第60回日本神経学会学術大会

セッション情報

シンポジウム

[S-27] Current topics in Guillain-Barré syndrome - from pathophysiology to clinical features

2019年5月24日(金) 13:45 〜 15:45 第6会場 (大阪国際会議場10F 会議室1009)

座長:海田 賢一(防衛医科大学校内科学3 神経・抗加齢血管内科), 千葉 厚郎(杏林大学医学部神経内科)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

Hugh Willison (University of Glasgow)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

千葉 厚郎 (杏林大学 神経内科)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

Bart Jacobs (Departments of Neurology and Immunology, Erasmus University Medical Center)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

桑原 聡 (千葉大学病院 脳神経内科)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.

山岸 裕子1, 桑原 基1, 鈴木 秀和1,2, 寒川 真1, Japanese GBS study group3, 楠 進1 (1.近畿大学 神経内科, 2.育和会記念病院 神経内科, 3.Japanese GBS study group)

This symposium is designed to introduce novel international studies of clinical and basic research from leading laboratories as well as to discuss current topics in the field of Guillain-Barré syndrome (GBS). The International GBS Outcome Study (IGOS) which has been just accomplished is a worldwide prospective, collaborative study of GBS, results of which will be global standards and provide evidence about a new clinical guideline of GBS. In addition, recently-reported new observations of antibody-mediated pathophysiology in GBS are expected to improve diagnostic approach, change the concept of electrophysiological categories, and develop promising immunotherapies and treatment strategy. This symposium will stimulate neurologists to absorb such novel knowledge and to put it to a practical use without regard to their specialty.